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RISKS AND OUTCOMES OF IDIOPATHIC PNEUMONIA SYNDROME 
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA- 
TION: THE INTENSITY OF THE CONDITIONING REGIMEN OUT- 
WEIGHS THE EFFECT OF ACUTE GRAFT-VERSUS-HOST DISEASE 
Fukuda, T.; Hack~mm, R.C.; Guthrie, K.A., Carter, R.A.; Sa;ld- 
maier, B.M.; Davis, C.; ~/lartin, P.ff.; &orb, R.F.; Madtes, D.K. 
Cli71ical Research DivisioT;, Fred Hittchil;soll Cancer Research Center, 
Seattle, f;I/~q. 
Background:Idiopathic pneumonia syndrome (IPS) is one of 
the major causes of mortality after allogeneic hematopoietic 
stem cell transplantation (HCT). Here, we investigated the 
incidence, risk factors and outcomes of IPS after myeloablative 
compared to nonmyeloablative allogeneic HCT. Methods:We 
retrospectively analyzed ata from patients who underwent 
allogeneic myeloablative (Conventional group; n=926) or non- 
myeloablative (NST group; n=183) HCT from related or 
unrelated onors at FHCRC between 12/1997 and 12/2001. 
IPS was diagnosed uring the first 120 days after transplant, 
based on NHLBI criteria including 1) multilobar infiltrates 
identified by CXR or CT scan, 2) symptoms/signs of pnemno- 
nia and evidence of abnormal physiology, and 3) absence of 
active lower respiratory tract infection. Survival was defined as 
alive 30 days after hospital discharge. Results:Patient charac- 
teristics and clinical course after IPS of the 2 groups are sum- 
marized in the Table. Multivariate analysis demonstrated that 
NST was associated with a significantly decreased risk of IPS 
(HR 0.24, p-0.001), while age greater than 40 years and 
grades 3-4 acute GVHD were associated with significantly 
increased risks (HR 1.8, p=0.009 and HR 3.4, p=0.001, respec- 
tively). Survival of IPS patients to 30 days past discharge was 
25% after either NST or conventional HCT. IPS patients who 
required mechanical ventilation (n=50) had a 2% survival 
while patients who did not require mechanical ventilation 
(n=31) had a 61% survival (p=0.001). The presence of renal 
failure at IPS onset (serum creatinine ~2 mg/dl) was associated 
with an increased probability for death before or within 30 
days of hospital discharge (OR 14, p=0.023) in a multiple 
logistic regression model. Conclusion:Recipients of NST 
have a significantly decreased risk of IPS compared to those 
given myeloablative conditioning despite greater patient age 
and similar incidence of severe acute GVHD. These findings 
suggest hat lung damage from myeloablative conditioning 
plays a crucial role in the development of IPS after transplant 
and that acute GVHD alone is insufficient to cause IPS. IPS is 
associated with a high mortality rate despite aggressive support 
when mechanical ventilation is required or renal failure is 
present. 
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TRAFFICKING OF EX VIVO EXPANDED DONOR DERIVED DENDRITIC 
CELLS AFTER ALLOGENEIC BMT 
Schi'mmelpfemfig, C.HJ; Tinnier, I.fI.2; Schulz, S.4; 3/lcBT"ide, J.M.2; 
Baker, ft.;; Fathmm;, C.G.2; Contag, C.H.S; Negrin, R.S. l 1. Stmzford 
U~liversity 3/ledical Cemel, Dpt. of MecliciJTe, Div. of BMT, Stallford, 
CA; 2. Dpt. of 3/ledici~ze, Div. of bnmunology and Rhemnatology, Stan- 
ford, CA; 3. Dpt. of Pediatrics, Div. of Neonatal mid Developme~;tal 
Medicitze, Sra~rd, CA; 4. Dpt. of Microbiology and bnm, unology, Div. 
of lt#ctious Diseases, Stal;ford, CA. 
Introduction: Little is known about survival and trafficking of ex 
vivo expanded DCs after adoptive transfer in animals. We investi- 
gated the trafficking patterns of allogeneie DCs transduced to 
express green fluorescence protein (gfp) and luciferase (iue) 
(gfp/luc + DCs) in mice that had received allogeneic BMT. Meth- 
ods: C57BL/6 BM was depleted of B220 ÷, CD3 + and GR-I + cells 
and was expanded for 7 days with GM-CSF, IL-4 and FIt3L. A 
retroviral vector encoding luc and gfp was used for transduction. 
Gfp/luc ÷ DCs were analyzed by FACS and injected i.v. at 4x106 
Des per animal into BALB/c mice that had received either allo- 
geneic myeloabiative BMT (BALB/c-mbl, n=5) or non-myeloabla- 
tive (BALB/e-n/mbl, n=5) BMT of C57BL/6 BM donor mice 10 
weeks prior. The hz vivo trafficking of the gfp/luc+DCs was moni- 
tored by biolmninescent imaging (BLI). Tissues were examined 
for gfp+ DCs using immunohistoehemistry. Results: Expanded 
C57BL/6 DCs expressed CD80, CD86 and MHC II. After trans- 
duction, CD 1 lc + gfp/Iuc + cells represented 20-27 % of viable cells. 
After injection , gfp/luc ÷ DCs were detectable in BALB/c-mbl and 
BALB/c-n/mbl mice over the entire observation period (BALB/c- 
mbl: 45d, BALB/c-n/mbh 101d). Immediately after injection, a 
high biolmninescent signal (BLS) was detected in the puhnonat y 
area. In BALB/c-mbl this signal decreased constantly until dl0, 
while in the BALB/c-n/mbl the BLS decreased on d2 and 
remained stable until d23. In both groups on d2 and d7 BLSs were 
detected in the area of liver and spleen. Starting on dl0 in 
BALB/c-mbl and on d23 in the BALB/c-n/mbl there was an 
increase of the BLS reaching amaximum in BALB/c-mbl on d35 
and in BALB/c-n/mbl on d77. The increase of the BLS was seen 
in both groups in the area of the gut, the spleen and the thymus. 
These findings were confirmed by immunohistochemistry of gut 
and spleen sections which showed gfp+CDllc +DCs. During the 
observation period no animal exhibited signs of GvHD. Conclu- 
sion: Here, we show that donor-derived, exvivo expanded gfp/luc + 
DCs survive in hosts after allogeneic BMT. They nfigrate to thy- 
mus, spleen and gut, but mice develop no clinical signs of GVHD. 
The ability to visualize DC survival and trafficking in an allogene- 
ic BMT setting will aid in the optimization of DC based treatment 
strategies. 
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IMPROVING OUTCOMES OF HAPLOIDENTICAL TRANSPLANTS FOR 
ACUTE LEUKEMIA 
Aversa, F.;; Terenzi, .4.1; Balkwti, S.1; Felici;~i, RJ; Carotti, 4.1; Fal- 
ciTzelli, F J; Tabilio, A J; Falzetti, F.z; Velardi, A J; &mtucci, A J; Reis- 
he15 I7.21 Martelli, AI.F. 1 1. Hematology, Perztgia, Perltgia, Italy; 
2. ~Veizmann Imtitute, Rehovot, Israel. 
Our first report on 36 acute leukemia p tients howed a mega- 
dose of T-depleted HSC is crucial factor in promoting engraft- 
ment across the HLA barriers. Modifications to our approach 
have led to remarkable progress. In 1995 fludarabine replaced 
cyclophosphamide in our TBI-based conditioning regimen and we 
started to select he CD34+ cells using the Ceprate system (44 
patients). In 1999, we changed to the CliniMacs device and sus- 
pended post transplant G-CSF (65 patients). Population included 
145 patients (age range: 2 - 62 years), 76 AML and 69 ALL, at 
high-risk of relapse because of disease status at transplant (27 bad- 
risk CR I, 48 CR &#61619; II, 70 in relapse). Disease status was 
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